Pathology of adrenocortical tumors: Review and recent data;Anatomie pathologique des tumeurs corticosurrénaliennes de l'adulte : état des lieux et données récentes

Annales d'Endocrinologie

Volumn 70, Issue 3, 2009, Pages 179-185

  Tissier, F ^a,b,c,d  

^a AP HP ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT COCHIN   (France)

^d Réseau De Recherche Clinique Comète   (France)

Author keywords

Adenocortical adenoma; Adenocortical carcinoma; Adenocortical tumor; Adrenal; Adrenal cortex; Cyclin E; IGF II; Immunohistochemistry; Ki 67; P53; Wnt catenin signaling pathway

Indexed keywords

MOLECULAR MARKER;

ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ARTICLE; DIFFERENTIAL DIAGNOSIS; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MORPHOLOGY; PATHOLOGY; PROGNOSIS;

ADRENAL CORTEX NEOPLASMS; BETA CATENIN; CYCLIN E; GENE EXPRESSION REGULATION, NEOPLASTIC; INSULIN-LIKE GROWTH FACTOR II; MITOSIS; MUTATION; NECROSIS; NEOPLASM METASTASIS; PHEOCHROMOCYTOMA; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67349211826     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2009.02.014     Document Type: Article

References (77)

1. DeLellis R.A.L.R., Heitz P.U., and Eng C. Pathology and genetics. Tumors of endocrine organs. World Health Organization Classification of Tumors (2004)
2. Terzolo M., Angeli A., Fassnacht M., Daffara F., Tauchmanova L., Conton P.A., et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356 (2007) 2372-2380
3. Kirschner L.S. Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab 91 (2006) 14-21
4. Groussin L., Bertherat J., Gicquel C., le Bouc Y., and Bertagna X. Insights into the molecular biology of adrenocortical tumors. Exp Clin Endocrinol Diabetes 115 (2007) 175-178
5. Aubert S., Buob D., Leroy X., Devos P., Carnaille B., Do Cao C., et al. Weiss system: a still in-use diagnostic tool for the assessment of adrenocortical malignancy. Ann Pathol 25 (2005) 545-554
6. Giordano T.J. Molecular pathology of adrenal cortical tumors: separating adenomas from carcinomas. Endocr Pathol 17 (2006) 355-363
7. Young W.F. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 66 (2007) 607-618
8. McNicol A.M. Lesions of the adrenal cortex. Arch Pathol Lab Med 132 (2008) 1263-1271
9. Lack E.E. Tumors of the adrenal gland and extra-adrenal paraganglia (1995), Atlas of tumor pathology, Washington, DC
10. Ross N.S., and Aron D.C. Hormonal evaluation of the patient with an incidentally discovered adrenal mass. N Engl J Med 323 (1990) 1401-1405
11. Hoang M.P., Ayala A.G., and Albores-Saavedra J. Oncocytic adrenocortical carcinoma: a morphologic, immunohistochemical and ultrastructural study of four cases. Mod Pathol 15 (2002) 973-978
12. Lin B.T., Bonsib S.M., Mierau G.W., Weiss L.M., and Medeiros L.J. Oncocytic adrenocortical neoplasms: a report of seven cases and review of the literature. Am J Surg Pathol 22 (1998) 603-614
13. el-Naggar A.K., Evans D.B., and Mackay B. Oncocytic adrenal cortical carcinoma. Ultrastruct Pathol 15 (1991) 549-556
14. Tanaka K., Kumano Y., Kanomata N., Takeda M., Hara I., Fujisawa M., et al. Oncocytic adrenocortical carcinoma. Urology 64 (2004) 376-377
15. Sturm N., Moulai N., Laverriere M.H., Chabre O., Descotes J.L., and Brambilla E. Primary adrenocortical sarcomatoid carcinoma: case report and review of literature. Virchows Arch 452 (2008) 215-219
16. Lee M.S., Park I.A., Chi J.G., Ham E.K., Lee K.C., and Lee C.W. Adrenal carcinosarcoma--a case report. J Korean Med Sci 12 (1997) 374-377
17. Decorato J.W., Gruber H., Petti M., and Levowitz B.S. Adrenal carcinosarcoma. J Surg Oncol 45 (1990) 134-136
18. Fischler D.F., Nunez C., Levin H.S., McMahon J.T., Sheeler L.R., and Adelstein D.J. Adrenal carcinosarcoma presenting in a woman with clinical signs of virilization. A case report with immunohistochemical and ultrastructural findings. Am J Surg Pathol 16 (1992) 626-631
19. Komminoth P., Roth J., Schroder S., Saremaslani P., and Heitz P.U. Overlapping expression of immunohistochemical markers and synaptophysin mRNA in pheochromocytomas and adrenocortical carcinomas. Implications for the differential diagnosis of adrenal gland tumors. Lab Invest 72 (1995) 424-431
20. Cote R.J., Cordon-Cardo C., Reuter V.E., and Rosen P.P. Immunopathology of adrenal and renal cortical tumors. Coordinated change in antigen expression is associated with neoplastic conversion in the adrenal cortex. Am J Pathol 136 (1990) 1077-1084
21. Volante M., Buttigliero C., Greco E., Berruti A., and Papotti M. Pathological and molecular features of adrenocortical carcinoma: an update. J Clin Pathol 61 (2008) 787-793
22. Gaffey M.J., Traweek S.T., Mills S.E., Travis W.D., Lack E.E., Medeiros L.J., et al. Cytokeratin expression in adrenocortical neoplasia: an immunohistochemical and biochemical study with implications for the differential diagnosis of adrenocortical, hepatocellular, and renal cell carcinoma. Hum Pathol 23 (1992) 144-153
23. Schroder S., Padberg B.C., Achilles E., Holl K., Dralle H., and Kloppel G. Immunocytochemistry in adrenocortical tumours: a clinicomorphological study of 72 neoplasms. Virchows Arch A Pathol Anat Histopathol 420 (1992) 65-70
24. Loy T.S., Phillips R.W., and Linder C.L. A103 immunostaining in the diagnosis of adrenal cortical tumors: an immunohistochemical study of 316 cases. Arch Pathol Lab Med 126 (2002) 170-172
25. Busam K.J., Chen Y.T., Old L.J., Stockert E., Iversen K., Coplan K.A., et al. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol 22 (1998) 976-982
26. Ghorab Z., Jorda M., Ganjei P., Nadji M., and Melan A. (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas. Appl Immunohistochem Mol Morphol 11 (2003) 330-333
27. Busam K.J., Iversen K., Coplan K.A., Old L.J., Stockert E., Chen Y.T., et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol 22 (1998) 57-63
28. Pan C.C., Chen P.C., Tsay S.H., and Ho D.M. Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique. Appl Immunohistochem Mol Morphol 13 (2005) 347-352
29. Arola J., Liu J., Heikkila P., Ilvesmaki V., Salmenkivi K., Voutilainen R., et al. Expression of inhibin alpha in adrenocortical tumours reflects the hormonal status of the neoplasm. J Endocrinol 165 (2000) 223-229
30. Fetsch P.A., Powers C.N., Zakowski M.F., and Abati A. Anti-alpha-inhibin: marker of choice for the consistent distinction between adrenocortical carcinoma and renal cell carcinoma in fine-needle aspiration. Cancer 87 (1999) 168-172
31. Jorda M., De M.B., Nadji M., and Calretinin. Inhibin are useful in separating adrenocortical neoplasms from pheochromocytomas. Appl Immunohistochem Mol Morphol 10 (2002) 67-70
32. Varma V., and Cohen C. Immunohistochemical and molecular markers in the diagnosis of hepatocellular carcinoma. Adv Anat Pathol 11 (2004) 239-249
33. Kakar S., Gown A.M., Goodman Z.D., and Ferrell L.D. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med 131 (2007) 1648-1654
34. Weiss L.M. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8 (1984) 163-169
35. van Slooten H., Schaberg A., Smeenk D., and Moolenaar A.J. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 55 (1985) 766-773
36. Hough A.J., Hollifield J.W., Page D.L., and Hartmann W.H. Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data. Am J Clin Pathol 72 (1979) 390-399
37. Aubert S., Wacrenier A., Leroy X., Devos P., Carnaille B., Proye C., et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol 26 (2002) 1612-1619
38. van't Sant H.P., Bouvy N.D., Kazemier G., Bonjer H.J., Hop W.C., Feelders R.A., et al. The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas. Histopathology 51 (2007) 239-245
39. Blanes A., and Diaz-Cano S.J. Histologic criteria for adrenocortical proliferative lesions: value of mitotic figure variability. Am J Clin Pathol 127 (2007) 398-408
40. Weiss L.M., Medeiros L.J., and Vickery Jr. A.L. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13 (1989) 202-206
41. Wagner M., Walter P.R., Ghnassia J.P., and Gasser B. Adrenocortical tumors. I. Prognostic evaluation of a series of 17 cases using the Weiss criteria. Ann Pathol 13 (1993) 306-311
42. Gicquel C., Bertagna X., Gaston V., Coste J., Louvel A., Baudin E., et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61 (2001) 6762-6767
43. Bisceglia M., Ludovico O., Di Mattia A., Ben-Dor D., Sandbank J., Pasquinelli G., et al. Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. Int J Surg Pathol 12 (2004) 231-243
44. Assie G., Antoni G., Tissier F., Caillou B., Abiven G., Gicquel C., et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 92 (2007) 148-154
45. McNicol A.M., Struthers A.L., Nolan C.E., Hermans J., and Haak H.R. Proliferation in adrenocortical tumors: correlation with clinical outcome and p53 Status. Endocr Pathol 8 (1997) 29-36
46. Nakazumi H., Sasano H., Iino K., Ohashi Y., and Orikasa S. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. Mod Pathol 11 (1998) 1165-1170
47. Terzolo M., Boccuzzi A., Bovio S., Cappia S., De Giuli P., Ali A., et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology 57 (2001) 176-182
48. Kiiveri S., Liu J., Arola J., Heikkila P., Kuulasmaa T., Lehtonen E., et al. Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors. Mol Cell Endocrinol 233 (2005) 47-56
49. Arola J., Salmenkivi K., Liu J., Kahri A.I., and Heikkila P. p53 and Ki67 in adrenocortical tumors. Endocr Res 26 (2000) 861-865
50. Bernini G.P., Moretti A., Viacava P., Bonadio A.G., Iacconi P., Miccoli P., et al. Apoptosis control and proliferation marker in human normal and neoplastic adrenocortical tissues. Br J Cancer 86 (2002) 1561-1565
51. Wachenfeld C., Beuschlein F., Zwermann O., Mora P., Fassnacht M., Allolio B., et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful?. Eur J Endocrinol 145 (2001) 335-341
52. Stojadinovic A., Brennan M.F., Hoos A., Omeroglu A., Leung D.H., Dudas M.E., et al. Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis. Mod Pathol 16 (2003) 742-751
53. Morimoto R., Satoh F., Murakami O., Suzuki T., Abe T., Tanemoto M., et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J 55 (2008) 49-55
54. Libe R., Fratticci A., and Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14 (2007) 13-28
55. Libe R., Groussin L., Tissier F., Elie C., Rene-Corail F., Fratticci A., et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res 13 (2007) 844-850
56. Libe R., and Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol 153 (2005) 477-487
57. Reincke M., Wachenfeld C., Mora P., Thumser A., Jaursch-Hancke C., Abdelhamid S., et al. p53 mutations in adrenal tumors: Caucasian patients do not show the exon 4 "hot spot" found in Taiwan. J Clin Endocrinol Metab 81 (1996) 3636-3638
58. Lin S.R., Lee Y.J., and Tsai J.H. Mutations of the p53 gene in human functional adrenal neoplasms. J Clin Endocrinol Metab 78 (1994) 483-491
59. Schmitt A., Saremaslani P., Schmid S., Rousson V., Montani M., Schmid D.M., et al. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology 49 (2006) 298-307
60. McNicol A.M., Nolan C.E., Struthers A.J., Farquharson M.A., Hermans J., and Haak H.R. Expression of p53 in adrenocortical tumours: clinicopathological correlations. J Pathol 181 (1997) 146-152
61. Barzon L., Chilosi M., Fallo F., Martignoni G., Montagna L., Palu G., et al. Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors. Eur J Endocrinol 145 (2001) 207-212
62. Wilkin F., Gagne N., Paquette J., Oligny L.L., and Deal C. Pediatric adrenocortical tumors: molecular events leading to insulin-like growth factor II gene overexpression. J Clin Endocrinol Metab 85 (2000) 2048-2056
63. Bourcigaux N., Gaston V., Logie A., Bertagna X., Le Bouc Y., and Gicquel C. High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors. J Clin Endocrinol Metab 85 (2000) 322-330
64. Tissier F., Louvel A., Grabar S., Hagnere A.M., Bertherat J., Vacher-Lavenu M.C., et al. Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumors. Eur J Endocrinol 150 (2004) 809-817
65. Moon R.T., Kohn A.D., De Ferrari G.V., and Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5 (2004) 691-701
66. Logan C.Y., and Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20 (2004) 781-810
67. Giles R.H., van Es J.H., and Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653 (2003) 1-24
68. Wakatsuki S., Sasano H., Matsui T., Nagashima K., Toyota T., and Horii A. Adrenocortical tumor in a patient with familial adenomatous polyposis: a case associated with a complete inactivating mutation of the APC gene and unusual histological features. Hum Pathol 29 (1998) 302-306
69. Blaker H., Sutter C., Kadmon M., Otto H.F., Von Knebel-Doeberitz M., Gebert J., et al. Analysis of somatic APC mutations in rare extracolonic tumors of patients with familial adenomatous polyposis coli. Genes Chromosomes Cancer 41 (2004) 93-98
70. Giordano T.J., Thomas D.G., Kuick R., Lizyness M., Misek D.E., Smith A.L., et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 162 (2003) 521-531
71. Tissier F., Cavard C., Groussin L., Perlemoine K., Fumey G., Hagnere A.M., et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 65 (2005) 7622-7627
72. Gaujoux S., Tissier F., Groussin L., Libe R., Ragazzon B., Launay P., et al. Wnt/beta-catenin and 3', 5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab 93 (2008) 4135-4140
73. Macfarlane D.A. Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of 55 cases. Ann R Coll Surg Engl 23 (1958) 155-186
74. Sidhu S., Gicquel C., Bambach C.P., Campbell P., Magarey C., Robinson B.G., et al. Clinical and molecular aspects of adrenocortical tumourigenesis. ANZ J Surg 73 (2003) 727-738
75. Harrison L.E., Gaudin P.B., and Brennan M.F. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 134 (1999) 181-185
76. Edgren M., Eriksson B., Wilander E., Westlin J.E., Nilsson S., and Oberg K. Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas. Anticancer Res 17 (1997) 1303-1309
77. Fuhrman S.A., Lasky L.C., and Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6 (1982) 655-663